These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2971 related articles for article (PubMed ID: 17296351)

  • 41. Genetic and epigenetic SLC18A2 silencing in prostate cancer is an independent adverse predictor of biochemical recurrence after radical prostatectomy.
    Sørensen KD; Wild PJ; Mortezavi A; Adolf K; Tørring N; Heebøll S; Ulhøi BP; Ottosen P; Sulser T; Hermanns T; Moch H; Borre M; Ørntoft TF; Dyrskjøt L
    Clin Cancer Res; 2009 Feb; 15(4):1400-10. PubMed ID: 19228741
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The new frontier in cancer research: deciphering cancer epigenetics.
    Lohrum M; Stunnenberg HG; Logie C
    Int J Biochem Cell Biol; 2007; 39(7-8):1450-61. PubMed ID: 17442611
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Epigenetics of lung cancer.
    Bowman RV; Yang IA; Semmler AB; Fong KM
    Respirology; 2006 Jul; 11(4):355-65. PubMed ID: 16771905
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Molecular detection of prostate cancer: a role for GSTP1 hypermethylation.
    Henrique R; Jerónimo C
    Eur Urol; 2004 Nov; 46(5):660-9; discussion 669. PubMed ID: 15474280
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The fundamental role of epigenetics in hematopoietic malignancies.
    Galm O; Herman JG; Baylin SB
    Blood Rev; 2006 Jan; 20(1):1-13. PubMed ID: 16426940
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prevention of benign prostatic hyperplasia disease.
    Marks LS; Roehrborn CG; Andriole GL
    J Urol; 2006 Oct; 176(4 Pt 1):1299-306. PubMed ID: 16952616
    [TBL] [Abstract][Full Text] [Related]  

  • 47. DNA demethylating agents and epigenetic therapy of cancer.
    Mani S; Herceg Z
    Adv Genet; 2010; 70():327-40. PubMed ID: 20920754
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Epigenetic profiles distinguish malignant pleural mesothelioma from lung adenocarcinoma.
    Goto Y; Shinjo K; Kondo Y; Shen L; Toyota M; Suzuki H; Gao W; An B; Fujii M; Murakami H; Osada H; Taniguchi T; Usami N; Kondo M; Hasegawa Y; Shimokata K; Matsuo K; Hida T; Fujimoto N; Kishimoto T; Issa JP; Sekido Y
    Cancer Res; 2009 Dec; 69(23):9073-82. PubMed ID: 19887624
    [TBL] [Abstract][Full Text] [Related]  

  • 49. High promoter methylation levels of APC predict poor prognosis in sextant biopsies from prostate cancer patients.
    Henrique R; Ribeiro FR; Fonseca D; Hoque MO; Carvalho AL; Costa VL; Pinto M; Oliveira J; Teixeira MR; Sidransky D; Jerónimo C
    Clin Cancer Res; 2007 Oct; 13(20):6122-9. PubMed ID: 17947477
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Unraveling the epigenetic code of cancer for therapy.
    Smith LT; Otterson GA; Plass C
    Trends Genet; 2007 Sep; 23(9):449-56. PubMed ID: 17681396
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A new paradigm in toxicology and teratology: altering gene activity in the absence of DNA sequence variation.
    Reamon-Buettner SM; Borlak J
    Reprod Toxicol; 2007 Jul; 24(1):20-30. PubMed ID: 17596910
    [TBL] [Abstract][Full Text] [Related]  

  • 52. DNA methylation, molecular genetic, and linkage studies in prostate cancer.
    Jarrard DF; Bova GS; Isaacs WB
    Prostate Suppl; 1996; 6():36-44. PubMed ID: 8630228
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Towards targeted epigenetic therapy of cancer.
    Magic Z; Supic G; Brankovic-Magic M
    J BUON; 2009 Sep; 14 Suppl 1():S79-88. PubMed ID: 19785074
    [TBL] [Abstract][Full Text] [Related]  

  • 54. CpG island hypermethylation at multiple gene sites in diagnosis and prognosis of prostate cancer.
    Ellinger J; Bastian PJ; Jurgan T; Biermann K; Kahl P; Heukamp LC; Wernert N; Müller SC; von Ruecker A
    Urology; 2008 Jan; 71(1):161-7. PubMed ID: 18242387
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis.
    Clark SJ
    Hum Mol Genet; 2007 Apr; 16 Spec No 1():R88-95. PubMed ID: 17613553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Epigenetics and cancer: implications for drug discovery and safety assessment.
    Moggs JG; Goodman JI; Trosko JE; Roberts RA
    Toxicol Appl Pharmacol; 2004 May; 196(3):422-30. PubMed ID: 15094313
    [TBL] [Abstract][Full Text] [Related]  

  • 57. DNA methylation changes in ovarian cancer: implications for early diagnosis, prognosis and treatment.
    Barton CA; Hacker NF; Clark SJ; O'Brien PM
    Gynecol Oncol; 2008 Apr; 109(1):129-39. PubMed ID: 18234305
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Epigenetic biomarkers in prostate cancer: Current and future uses.
    Chiam K; Ricciardelli C; Bianco-Miotto T
    Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Epigenetic and chromatin modifiers as targeted therapy of hematologic malignancies.
    Bhalla KN
    J Clin Oncol; 2005 Jun; 23(17):3971-93. PubMed ID: 15897549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prostate cancer stem cells, telomerase biology, epigenetic modifiers, and molecular systemic therapy for the androgen-independent lethal phenotype.
    Koeneman KS
    Urol Oncol; 2006; 24(2):119-21. PubMed ID: 16520275
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 149.